PM
ESPR icon

Prosight Management’s Esperion Therapeutics ESPR Stock Holding History

Prosight Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-48,800
Closed -$1.91M – 34
2018
Q2 		$1.91M Buy
+48,800
New +$2.47M 1.4% 21

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Prosight Management's ESPR Position: Q3 2018 in Review

Prosight Management sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 48,800 shares — an estimated $1.91M sold.

Prosight Management first reported a position in ESPR in Q2 2018 and held it in 1 quarter. The position peaked at $1.91M in Q2 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Prosight Management reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Prosight Management sold 48,800 Esperion Therapeutics shares in Q3 2018, an estimated $1.91M.
  • Prosight Management first reported a position in Esperion Therapeutics in Q2 2018 and held it in 1 quarter.
  • Prosight Management's Esperion Therapeutics position peaked at $1.91M in Q2 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Prosight Management's 13F filing for Q3 2018, filed 15 Nov 2018.